GlassScriptPhysician profile
Peter T Filipov
NPI 1811990039
$909.22
in general payments reported to CMS, 2019-2025
13 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.29 · 2021: $23.41 · 2022: $142 · 2023: $99.50 · 2024: $303 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $239.06 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $186.71 | 2024-2025 | Acthar |
| Alcon Vision LLC | $133.58 | 2021-2024 | Clareon |
| Rayner Intraocular Lenses Limited | $98.41 | 2022-2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Tarsus Pharmaceuticals, INC. | $52.31 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $46.02 | 2023-2025 | Cequa |
| Oyster Point Pharma, INC. | $32.36 | 2022 | |
| Dompe US, INC. | $29.91 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $20.50 | 2019 | |
| Bausch & Lomb Americas INC. | $20.02 | 2024 | Xiidra, Miebo |
| Allergan, INC. | $18.79 | 2019 | |
| Sight Sciences, INC. | $17.92 | 2022 | |
| Amgen INC. | $13.63 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Filipov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.